Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -15,6 +15,9 @@
15	15	Bausch Health Companies Inc. (TSX: BHC, NYSE: BHC) is a global, diversified pharmaceutical company. The company develops, manufactures and markets a range of products primarily in gastroenterology, neurology, dermatology and international pharmaceuticals. The company manufacture and market a broad range of branded and generic pharmaceuticals, and over-the-counter (OTC) products directly or indirectly in more than 90 countries and regions, including the United States, Canada, Europe, the Middle East, Africa, Asia Pacific and Latin America.
16	16
17	17
	18	+[[image:BHC1.jpg]]
	19	+
	20	+
18	18	= Financial Highlights =
19	19
20	20	**Bausch Health Announces Second-Quarter 2022 Results**
...	...	@@ -68,7 +68,7 @@
68	68	GAAP Earnings Per Share attributable to Bausch Health for the second quarter of 2022 was ($0.40), as compared to ($1.66) for the second quarter of 2021.
69	69
70	70
71		-Adjusted EBITD Aattributable to Bausch Health (non-GAAP)
	74	+**Adjusted EBITD Aattributable to Bausch Health (non-GAAP)**
72	72
73	73
74	74	Adjusted EBITDA attributable to Bausch Health (non-GAAP) was $701 million for the second quarter of 2022, as compared to $826 million for the second quarter of 2021, a decrease of $125 million, primarily due to the divestment of Amoun, lower gross profit as discussed above and higher investments in sales and marketing and research and development.
...	...	@@ -101,31 +101,23 @@
101	101	Full year Adjusted EBITDA (non-GAAP) range of $3.02 - $3.12 billion compared to prior guidance of $3.225 - $3.375 billion.
102	102
103	103
	107	+[[image:BHC2.png]]
104	104
105	105
	110	+= Business Overview =
106	106
107		-Business Overview
	112	+The company develop, manufacture and market, primarily in the therapeutic areas of gastroenterology (“GI”) and dermatology, and eye health, a broad range of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) over-the-counter (“OTC”) products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in approximately 100 countries.{{footnote}}https://fintel.io/doc/sec-bausch-health-companies-inc-885590-10qa-2022-september-02-19237-3443{{/footnote}}
108	108
109		-The company develop, manufacture and market, primarily in the therapeutic areas of gastroenterology (“GI”) and dermatology, and eye health, a broad range of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) over-the-counter (“OTC”) products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in approximately 100 countries.
110	110
111		-[[https:~~/~~/fintel.io/doc/sec-bausch-health-companies-inc-885590-10qa-2022-september-02-19237-3443>>https://fintel.io/doc/sec-bausch-health-companies-inc-885590-10qa-2022-september-02-19237-3443]]
112		-
113		-
114	114	The company's portfolio of products falls into five operating and reportable segments
115	115
116		-.
	117	+* **The Salix segment** consists of sales in the U.S. of GI products. Sales of the Xifaxan® product line represented 81% and 80% of the Salix segment’s revenues for the three and six months ended June 30, 2022, respectively.
	118	+* **The International segment** consists of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products.
	119	+* **The Diversified Products segment** consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products, (iii) Ortho Dermatologics (dermatological) products and (iv) dentistry products.
	120	+* **The Solta Medical segment** consists of global sales of Solta aesthetic medical devices.
	121	+* **The Bausch + Lomb segment** consists of global sales of Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals products.
117	117
118		-The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan® product line represented 81% and 80% of the Salix segment’s revenues for the three and six months ended June 30, 2022, respectively.
119	119
120		-The International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products.
121		-
122		-The Diversified Products segment consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products, (iii) Ortho Dermatologics (dermatological) products and (iv) dentistry products.
123		-
124		-The Solta Medical segment consists of global sales of Solta aesthetic medical devices.
125		-
126		-The Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals products.
127		-
128		-
129	129	The Company changed its segment structure. The new segment structure resulted in a change to the Company’s former Ortho Dermatologics segment whereby its medical dermatology business (Ortho Dermatologics) is now managed by the Chief Operating Decision Maker (“CODM”) as part of the Diversified Products segment and the Solta Medical business is now managed by the CODM as its own operating and reportable segment.
130	130
131	131	Separation of the Bausch + Lomb Eye Health Business